Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma
Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the potential role for the next-generation Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).
Zanubrutinib is the newest BTK inhibitor to appear in the treatment landscape for patients with MCL, but it does not have significant follow-up time yet, Wang says. There are many interesting points for the role of zanubrutinib in MCL, and it is an active agent, according to Wang. This agent receivedpriority review from the FDA in August 2019 for the treatment of patients with MCLwho have received at least 1 prior treatment.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
